(美国商业资讯)-- 百奥赛图(HKEX:02315),一家创新技术驱动新药研发的国际性生物技术公司,今日宣布与全球肿瘤治疗创新公司百济神州达成抗体分子的全球许可协议。本新闻稿包含多媒体。此处查看新闻稿全文: https://www.businesswire.com/news/home/20250709152706/zh-CN/百济神州此前已获得百奥赛图RenMice®全人抗体平台的授权使用许可,...
Source Link(美国商业资讯)-- 百奥赛图(HKEX:02315),一家创新技术驱动新药研发的国际性生物技术公司,今日宣布与全球肿瘤治疗创新公司百济神州达成抗体分子的全球许可协议。本新闻稿包含多媒体。此处查看新闻稿全文: https://www.businesswire.com/news/home/20250709152706/zh-CN/百济神州此前已获得百奥赛图RenMice®全人抗体平台的授权使用许可,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.